According to a recent LinkedIn post from Bright Uro, The Howard Center for Women’s Health has become the first gynecology practice in the U.S., and the first practice of any specialty in Georgia, to offer the company’s Glean urodynamics technology. The post cites comments from Dr. Drew Howard indicating an intention to expand urodynamics services across 12 clinic locations.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post highlights that Glean is positioned as enabling more convenient and comfortable urodynamics testing closer to patients’ homes. For investors, this early clinical adoption in a multi-site women’s health group may signal traction in a key target segment and suggest a pathway to recurring utilization-based revenue if broader rollouts follow.
As shared in the post, the plan to extend urodynamics to all locations at The Howard Center could provide a proof-of-concept for scaling Glean within regional health systems. If replicated with additional practices, such deployments could strengthen Bright Uro’s competitive position in urodiagnostics and potentially support future pricing power or partnership discussions.
The emphasis on innovation and patient experience in the LinkedIn content also suggests Bright Uro is aligning its value proposition with workflow efficiency and patient comfort, both important drivers in outpatient specialty care. While no financial metrics are mentioned, increased adoption in gynecology may expand the addressable market beyond traditional urology practices and diversify the company’s revenue base over time.